Canadian Agency for Drugs and Technologies in Health

Agence canadienne des médicaments et des technologies de la santé

Common Drug Review: Past Learnings, Future Direction

Dr. Brian O'Rourke, Vice-President, Common Drug Review, CADTH

CAPT Symposium
April 21, 2009, Montreal

CADTH ACMTS



Common Drug Review – The Beginning

- Prior to CDR, public drug plans conducted separate drug reviews.
- First Ministers initiated the plan for a single review and listing process.
- CDR established in March 2002; began accepting submissions in September 2003.
- First recommendations issued in May 2004.

Common Drug Review – Mandate

- **Provide a single process for:**
  - conducting objective, rigorous, and timely reviews of the clinical and economic evidence for drugs, and
  - providing formulary listing **recommendations** to the publicly funded drug plans in Canada (except Quebec)
- **Formulary decisions are made by the drug plans**

"A young doctor makes a full graveyard."

Chinese Proverb

Drug Review Process



CDR Activity to March 31, 2009

Number of submissions	163
Number of priority reviews requested/granted	31/12
Number of final recommendations issued	128
Number of "list" recommendations	63
Number of "do not list" recommendations	65

CDR Successes

- Incorporates 18 processes into one
- Meets targeted timeframes 100% of time
- High quality clinical and pharmacoeconomic reviews
- ~92% agreement between CEDAC recommendations and drug plan decisions
- Information publicly available on CADTH web site
- Ongoing process improvements in response to feedback

CDR – Challenges and Opportunities

- **Relationship with industry**
  - **Individual manufacturers**
  - **Rx&D and BIOTECanada**
- **Input from patients and patient advocacy groups**
- **Media and political attention**
- **Capacity, timelines, transparency**
- **Information gaps and methodological issues**

A Comment on HESA

- **Parliamentary Committee study to review the role and effectiveness of CDR – December 2007**
- **Recommendations:**
  - Requirement for an independent, external evaluation
  - Enhance transparency of scientific and price information
  - Increase public involvement through open CEDAC meetings and a public advisory body
  - Create a distinct appeal process for CEDAC recommendations
  - Establish an approach for the review of drugs for rare disorders and first in class drugs

CADTH ACMTS


PHILIPS


CAUTION

CDR - Future Direction



Program Enhancement, Capacity Building

- **Program Enhancement**
  - Pre-NOC priority review submissions
  - Resubmissions based on a reduced price during the embargo period
  - Expanded criteria for resubmissions
- **Capacity Building**
  - Staffing, organizational structure, efficiencies
  - Transparency initiative

Transparency Documents

Additional documents to increase understanding of the CEDAC recommendation

- Overview of clinical and pharmacoeconomic reports
- Summary of CEDAC discussion relating to the drug
- Plain language version of Recommendation and Reasons for Recommendation

Manufacturer provided an opportunity to review documents

- To identify inaccuracies and confidential information for removal

Integration, Harmonization, Evaluation

- Internal integration



- External harmonization
- Program evaluation

Opportunities for Growth

Stay tuned!

For More Information

CADTH web site: **www.cadth.ca**